China Pharma Holdings Inc. (CPHI) Quality Score
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Above 30x, cash flow yield is thin
Below 2%, essentially flat
Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful
Business Quality & Capital Allocation
Heavy dilution above 5%
Contracted >2pp, margin pressure
Net debt/FCF of 16.7x, high leverage
Below 8%, may not cover cost of capital
China Pharma Holdings (CPHI) quality: score, margins and returns
China Pharma Holdings (CPHI) scores 15/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100, on -111.8% operating margins and -12.5% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is China Pharma Holdings (CPHI) a high-quality business?+
China Pharma Holdings scores 15 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -111.8% operating margin and a -12.5% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does China Pharma Holdings's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CPHI's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where China Pharma Holdings scores well and where it falls behind.
What is China Pharma Holdings's return on invested capital (ROIC)?+
China Pharma Holdings earns about -12.5% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CPHI's margins and growth on this scorecard to judge durability.
How profitable is China Pharma Holdings?+
China Pharma Holdings runs an operating margin of about -111.8% and a net margin of about -114.3%. Revenue has grown at roughly -17.5% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.
SourceQuality score computed from the 10-Q filed 11 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.